StockNews.AISignal intelligence
Alector, Inc. · NASDAQ · Healthcare
Browse public ALEC signals with their source context and measured market impact. Open any signal for its permanent analysis page.
GSK terminated its neuroscience collaboration with Alector on two experimental antibody drugs after both candidates faced clinical setbacks. The breakup could trim near-term upside for Alector but may free resources for other programs or partnerships. Investors will focus on potential milestone, royalty implications, data readouts, and any new collaboration opportunities.
View signal analysisAlector's trial failed to meet co-primary endpoints for frontotemporal dementia. Stock dropped 51% to $1.57, nearing its 52-week low. Company reducing workforce by 49% amid ongoing trials. William Blair downgraded ALEC from Outperform to Market Perform. Cash reserves expected to last through 2027 despite recent setbacks.
View signal analysisAlector's experimental drug failed in a late-stage trial, ending the study. The company plans to lay off nearly half its workforce due to this failure.
View signal analysisBank of America downgraded Alector due to AL002 program failure. AL002 missed primary endpoint in Alzheimer’s Phase 2 trial. Expected Phase 3 trial results may take until late 2025. Limited near-term milestones pressure Alector's stock performance. Analyst reduced price target from $9 to $1.
View signal analysisAlector's AL002 failed to slow Alzheimer's progression in Phase 2 trial. No positive effects on clinical endpoints; treatment caused MRI abnormalities. Company is stopping the long-term study and cutting workforce by 17%. Alector has $457.2 million cash, expected to fund operations through 2026. Analysts predict AbbVie may opt out of AL002 collaboration due to trial failure.
View signal analysisAL002 trial failed to slow Alzheimer's disease progression. No favorable treatment effects on clinical or functional endpoints observed. Alector reducing workforce by approximately 17% to align resources. $457.2 million in cash projected to last through 2026. William Blair downgraded outlook, removing AL002 from their model.
View signal analysis